169 related articles for article (PubMed ID: 31451071)
1. PGC-1α activator-induced fatty acid oxidation in tumor-infiltrating CTLs enhances effects of PD-1 blockade therapy in lung cancer.
Wan H; Xu B; Zhu N; Ren B
Tumori; 2020 Feb; 106(1):55-63. PubMed ID: 31451071
[TBL] [Abstract][Full Text] [Related]
2. PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8
Chowdhury PS; Chamoto K; Kumar A; Honjo T
Cancer Immunol Res; 2018 Nov; 6(11):1375-1387. PubMed ID: 30143538
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity.
Chamoto K; Chowdhury PS; Kumar A; Sonomura K; Matsuda F; Fagarasan S; Honjo T
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):E761-E770. PubMed ID: 28096382
[TBL] [Abstract][Full Text] [Related]
4. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
[TBL] [Abstract][Full Text] [Related]
5. OCT4&SOX2-specific cytotoxic T lymphocytes plus programmed cell death protein 1 inhibitor presented with synergistic effect on killing lung cancer stem-like cells in vitro and treating drug-resistant lung cancer mice in vivo.
Zhang X; Hu F; Li C; Zheng X; Zhang B; Wang H; Tao G; Xu J; Zhang Y; Han B
J Cell Physiol; 2019 May; 234(5):6758-6768. PubMed ID: 30382588
[TBL] [Abstract][Full Text] [Related]
6. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
7. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.
Sawada Y; Yoshikawa T; Shimomura M; Iwama T; Endo I; Nakatsura T
Int J Oncol; 2015 Jan; 46(1):28-36. PubMed ID: 25354479
[TBL] [Abstract][Full Text] [Related]
8. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
[TBL] [Abstract][Full Text] [Related]
9. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.
Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y
Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246
[TBL] [Abstract][Full Text] [Related]
10. 5-Aminolevulinic acid/sodium ferrous citrate enhanced the antitumor effects of programmed cell death-ligand 1 blockade by regulation of exhausted T cell metabolism in a melanoma model.
Hu X; Que W; Hirano H; Wang Z; Nozawa N; Ishii T; Ishizuka M; Ito H; Takahashi K; Nakajima M; Tanaka T; Zhu P; Guo WZ; Li XK
Cancer Sci; 2021 Jul; 112(7):2652-2663. PubMed ID: 33934440
[TBL] [Abstract][Full Text] [Related]
11. Development of adoptive immunotherapy with KK-LC-1-specific TCR-transduced γδT cells against lung cancer cells.
Ichiki Y; Shigematsu Y; Baba T; Shiota H; Fukuyama T; Nagata Y; So T; Yasuda M; Takenoyama M; Yasumoto K
Cancer Sci; 2020 Nov; 111(11):4021-4030. PubMed ID: 32780528
[TBL] [Abstract][Full Text] [Related]
12. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
Du B; Wen X; Wang Y; Lin M; Lai J
Int Immunopharmacol; 2020 Sep; 86():106694. PubMed ID: 32570034
[TBL] [Abstract][Full Text] [Related]
14. Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer.
Tanaka K; Chamoto K; Saeki S; Hatae R; Ikematsu Y; Sakai K; Ando N; Sonomura K; Kojima S; Taketsuna M; Kim YH; Yoshida H; Ozasa H; Sakamori Y; Hirano T; Matsuda F; Hirai T; Nishio K; Sakagami T; Fukushima M; Nakanishi Y; Honjo T; Okamoto I
Sci Transl Med; 2022 Dec; 14(675):eabq0021. PubMed ID: 36516270
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.
Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066
[TBL] [Abstract][Full Text] [Related]
16. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
17. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8
Shan CK; Du YB; Zhai XT; Wang YX; Li Y; Gong JH; Ge ZJ; Liu XJ; Zhen YS
Cancer Chemother Pharmacol; 2021 Mar; 87(3):425-436. PubMed ID: 33388950
[TBL] [Abstract][Full Text] [Related]
18. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
19. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.
Zhao S; Ren S; Jiang T; Zhu B; Li X; Zhao C; Jia Y; Shi J; Zhang L; Liu X; Qiao M; Chen X; Su C; Yu H; Zhou C; Zhang J; Camidge DR; Hirsch FR
Cancer Immunol Res; 2019 Apr; 7(4):630-643. PubMed ID: 30755403
[TBL] [Abstract][Full Text] [Related]
20. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
Palakurthi S; Kuraguchi M; Zacharek SJ; Zudaire E; Huang W; Bonal DM; Liu J; Dhaneshwar A; DePeaux K; Gowaski MR; Bailey D; Regan SN; Ivanova E; Ferrante C; English JM; Khosla A; Beck AH; Rytlewski JA; Sanders C; Laquerre S; Bittinger MA; Kirschmeier PT; Packman K; Janne PA; Moy C; Wong KK; Verona RI; Lorenzi MV
Cancer Immunol Res; 2019 Sep; 7(9):1457-1471. PubMed ID: 31331945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]